Ma N, Qiao H, Tao H, Gan X, et al. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients. Clin Res Hepatol Gastroenterol 2022 May 27:101962.
PMID: 35636681